title: [Analysis of Chemotherapy with Trastuzumab in Advanced Gastric Cancer].
abstract: OBJECTIVE
  Here, we investigated the efficacy of chemotherapy with trastuzumab for patients with advanced or recurrent gastric cancer.
  
  
  METHODS
  We investigated the progression free survival (PFS) and overall survival (OS) of advanced gastric cancer patients who received first-line chemotherapy with trastuzumab in our hospital.
  
  
  RESULTS
  After first-line chemotherapy, the median PFS and median OS of patients who received trastuzumab combined with capecitabine/cisplatin chemotherapy was not significantly longer than those of patients who received trastuzumab combined with S-1/cisplatin chemotherapy (PFS, 138 [95%CI: 118-187] vs 169 [95%CI: 83-251] days, p=0.9684; OS, 393 [95%CI: 240-469] vs 466 [95%CI: 256-482] days, p=0.4703). After second-line chemotherapy, the median PFS of patients who received trastuzumab plus irinotecan chemotherapy was not significantly longer than that of patients who received trastuzumab plus paclitaxel chemotherapy (PFS, 63 [95%CI: 52-266] vs 58 [95%CI: 26-184] days, p=0.5447).
authors.affiliation: Dept. of Gastroenterological Surgery, Osaka General Medical Center.
authors.forename: Junji
authors.initials: J
authors.lastname: Kawada
authors.forename: Rie
authors.initials: R
authors.lastname: Nakatsuka
authors.forename: Masaaki
authors.initials: M
authors.lastname: Motoori
authors.forename: Susumu
authors.initials: S
authors.lastname: Miyazaki
authors.forename: Katsuki
authors.initials: K
authors.lastname: Danno
authors.forename: Masaru
authors.initials: M
authors.lastname: Kubota
authors.forename: Chu
authors.initials: C
authors.lastname: Matsuda
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Fujitani
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwase
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Tsujinaka
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000068878:Trastuzumab / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000068878:Trastuzumab